Founded in 2005 by Pierre Charneau and his team, Theravectys is a French biotech company spun off from the Pasteur Institute, specialising in therapeutic vaccines and immuno-oncology based on lentiviral vectors. Building on more than twenty years of fundamental and translational research, it develops breakthrough technologies to target certain cancers and infectious diseases. Adrien Dassault participated in a fundraising campaign to support their scientific progress. The company remains an ambitious player in French biotechnology.
